Ayala Pharmaceuticals Inc. (AYLA): Price and Financial Metrics
AYLA Price/Volume Stats
| Current price | $0.50 | 52-week high | $7.31 |
| Prev. close | $0.48 | 52-week low | $0.36 |
| Day low | $0.44 | Volume | 137,700 |
| Day high | $0.57 | Avg. volume | 76,300 |
| 50-day MA | $0.53 | Dividend yield | N/A |
| 200-day MA | $1.37 | Market Cap | 7.46M |
AYLA Stock Price Chart Interactive Chart >
Ayala Pharmaceuticals Inc. (AYLA) Company Bio
Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, an oral injectable small molecule GSI that is in Phase I clinical trial for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was founded in 2017 and is based in Rehovot, Israel.
AYLA Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | -94.32% |
| 5-year | N/A |
| YTD | N/A |
| 2023 | 0.00% |
| 2022 | -95.30% |
| 2021 | -22.64% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...